Vesicular stomatitis virus (VSV) as a paradigm for predicting antiviral activity against Ebola virus (EBOV);EBOV enfeksiyonlarının tedavisi amacıyla ilaç geliştirme sürecinde VSV örneği

Marmara Pharmaceutical Journal

Volumn 19, Issue 2, 2015, Pages 141-152

  de Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

BCX4430; Ebola virus (EBOV); Favipiravir; Filoviridae; Pyrazofurin; Rhabdoviridae; SAH hydrolase; Vesicular stomatitis virus (VSV)

Indexed keywords

3 DEAZANEPLANOCIN A; 5 ETHYNYL 4 IMIDAZOLECARBOXAMIDE 1 RIBOSIDE; 5 FLUORO 1 BETA D RIBOFURANOSYLIMIDAZOLE 4 CARBOXAMIDE; ADENINE DERIVATIVE; ADENOSINE DERIVATIVE; AMIDE; CARBODINE; CHLOROQUINE; FAVIPIRAVIR; IMMUCILLIN A; INOSINATE DEHYDROGENASE INHIBITOR; INTERFERON; PIRAZOFURIN; POLYSACCHARIDE SULFATE; RIBAVIRIN; RNA POLYMERASE; S ADENOSYLHOMOCYSTEINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BIOSAFETY; CHEMICAL STRUCTURE; EBOLAVIRUS; FILOVIRIDAE; INFLUENZA; RHABDOVIRIDAE; VESICULOVIRUS; VIRUS ENTRY;

EID: 84931082442     PISSN: None     EISSN: 13090801     Source Type: Journal    
DOI: 10.12991/mpj.20151910461     Document Type: Article

References (74)

1. Isaacs A, Lindenmann J. Virus interference. I. Interferon. Proc Royal Soc London 1957;147: 258-67.
2. Pattyn S, Jacob W, van der Groen G, Piot P, Courteille G. Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire. Lancet 1977;309: 573-4.
3. De Clercq E, De Somer P. Protective effect of interferon and polyacrylic acid in newborn mice infected with a lethal dose of vesicular stomatitis virus. Life Sci 1968;7: 925-33.
4. Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, van Amerongen G, van Riel D, de Jong T, Itamura S, Chan KH, Tashiro M, Osterhaus AD. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 2004;10: 290-3.
5. Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A, Honko A, Yen JY, Geisbert J, Paragas J, Fritz E, Olinger G, Young HA, Rubins KH, Karp CL. Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis 2013;208: 310-8.
6. Baba M, Snoeck R, Pauwels R, De Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 1988;32: 1742-5.
7. Ito M, Baba M, Hirabayashi K, Matsumoto T, Suzuki M, Suzuki S, Shigeta S, De Clercq E. In vitro activity of mannan sulfate, a novel sulfated polysaccharide, against human immunodeficiency virus type 1 and other enveloped viruses. Eur J Clin Microbiol 1989;8: 171-3.
8. Baba M, Nakajima M, Schols D, Pauwels R, Balzarini J, De Clercq E. Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res 1988;9: 335-43.
9. Ueno R, Kuno S. Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine. Lancet 1987;i: 1379.
10. Ito M, Baba M, Sato A, Pauwels R, De Clercq E, Shigeta S. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res 1987;7: 361-7.
11. Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1988;85: 6132-6.
12. Mitsuya H, Looney DJ, Kuno S, Ueno R, Wong-Staal F, Broder S. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 1988;240: 646-9.
13. Schols D, De Clercq E, Balzarini J, Baba M, Witvrouw M, Hosoya M, Andrei G, Snoeck R, Neyts J, Pauwels R, Nagy M, Györgyi-Edelényi J, Machovich R, Horváth I, Löw M, Görög S. Sulphated polymers are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, respiratory syncytial virus, and toga-, arena- and retroviruses. Antivir Chem Chemother 1990;1: 233-40.
14. Witvrouw M, Desmyter J, De Clercq E. Antiviral portrait series: 4. Polysulfates as inhibitors of HIV and other enveloped viruses. Antivir Chem Chemother 1994;5: 345-59.
15. Witvrouw M, Este JA, Mateu MQ, Reymen D, Andrei G, Snoeck R, Ikeda S, Pauwels R, Bianchini NV, Desmyter J, De Clercq E. Activity of a sulfated polysaccharide extracted from the red seaweed Aghardhiella tenera against human immunodeficiency virus and other enveloped viruses. Antivir Chem Chemother 1994;5: 297-303.
16. Witvrouw M, De Clercq E. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen Pharmacol 1997;29: 497-511.
17. Witvrouw M, Fikkert V, Pluymers W, Matthews B, Mardel K, Schols D, Raff J, Debyser Z, De Clercq E, Holan G, Pannecouque C. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Mol Pharmacol 2000;58: 1100-8.
18. Witkowski JT, Robins RK, Sidwell RW, Simon LN. Design, synthesis, and broad spectrum antiviral activity of 1-β-Dribofuranosyl- 1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem 1972; 15: 1150-4.
19. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972;177: 705-6.
20. Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, Simon LN. Mechanism of action of 1-β-Dribofuranosyl- 1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci USA 1973;70: 1174-8.
21. De Clercq E, Luczak M, Reepmeyer JC, Kirk KL, Cohen LA. Fluoroimidazoles as antiviral agents and inhibitors of polynucleotide biosynthesis. Life Sci 1975;17: 187-94.
22. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989;11: S750-61.
23. De Clercq E, Cools M, Balzarini J, Snoeck R, Andrei G, Hosoya M, Shigeta S, Ueda T, Minakawa N, Matsuda A. Antiviralactivities of 5 - ethynyl - 1 - beta - D - ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob Agents Chemother 1991;35: 679-84.
24. Matsuda A, Minakawa N, Sasaki T, Ueda T. The design, synthesis and antileukemic activity of 5-alkynyl-1-beta-Dribofuranosylimidazole- 4-carboxamides. Chem Pharm Bull 1988;36: 2730-3.
25. Balzarini J, Karlsson A, Wang L, Bohman C, Horská K, Votruba I, Fridland A, Van Aerschot A, Herdewijn P, De C l e r cq E. E I C A R (5 - e t h y n y l - 1 - b e t a - D - ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. J Biol Chem 1993;268: 24591-8.
26. De Clercq E, Bernaerts R, Shealy YF, Montgomery JA. Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine. Biochem Pharmacol 1990;39: 319-25.
27. De Clercq E, Murase J, Marquez VE. Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. Biochem Pharmacol 1991;41: 1821-9.
28. Schabel FM Jr. The antiviral activity of 9-β-Darabinofuranosyladenine (Ara-A). Chemotherapy 1968;13: 321-38.
29. Adenine Arabinoside: An Antiviral Agent, eds. Pavan- Langston D, Buchanan RA, Alford CA, Raven Press, NY, 1975, p 425.
30. De Clercq E, Descamps J, Krajeswka E, Shugar D. Antiviral activity of O'-methylated derivatives of adenine arabinoside. Biochem Pharmacol 1977;26: 794-7.
31. De Clercq E, Descamps J, De Somer P, Holý A. (S)-9-(2,3- Dihydroxypropyl)adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity. Science 1978;200: 563-5.
32. De Clercq E, Montgomery JA. Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine. Antiviral Res 1983;3: 17-24.
33. De Clercq E, Cools M. Antiviral potency of adenosine a n a l o g u e s: c o r r e l a t i o n w i t h i n h i b i t i o n o f S-adenosylhomocysteine hydrolase. Biochem Biophys Res Commun 1985;129: 306-11.
34. De Clercq E, Bergstrom DE, Holý A, Montgomery JA. Broad-spectrum antiviral activity of adenosine analogues. Antiviral Res 1984;4: 119-33.
35. Bergstrom DE, Brattesani AJ, Ogawa MK, Reddy PA, Schweickert MJ, Balzarini J, De Clercq E. Antiviral activity of C-5 substituted tubercidin analogues. J Med Chem 1984;27: 285-92.
36. Giziewicz J, De Clercq E, Luczak M, Shugar D. Antiviral and antimetabolic activities of formycin and its N1-, N2-, 2'-Oand 3'-O-methylated derivatives. Biochem Pharmacol 1975;24: 1813-7.
37. De Clercq E, Balzarini J, Madej D, Hansske F, Robins MJ. Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin. J Med Chem 1987;30: 481-6.
38. De Clercq E. Antiviral and antimetabolic activities of neplanocins. Antimicrob Agents Chemother 1985;28: 84-9.
39. De Clercq E, Cools M, Balzarini, J, Marquez VE, Borcherding DR, Borchardt RT, Drach JC, Kitaoka S, Konno T. Broadspectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives. Antimicrob Agents Chemother 1989;33: 1291-7.
40. Cools M, De Clercq E. Correlation between the antiviral activity of acyclic and carbocyclic adenosine analogues in murine L929 cells and their inhibitory effect on L929 cells S-adenosylhomocysteine hydrolase. Biochem Pharmacol 1989;38: 1061-7.
41. De Clercq E. S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem Pharmacol 1987;36: 2567-75.
42. Bray M, Driscoll J, Huggins JW. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-Lhomocysteine hydrolase inhibitor. Antiviral Res 2000;45: 135-47.
43. Bray M, Raymond JL, Geisber t T, Baker RO. 3-Deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice. Antiviral Res 2002;55: 151-9.
44. Patil SD, Schneller SW, Hosoya M, Snoeck R, Andrei G, Balzarini J, De Clercq,, E. Synthesis and antiviral properties of (±)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design. J Med Chem 1992;35: 3372-7.
45. Siddiqi SM, Chen X, Schneller SW, Ikeda S, Snoeck R, Andrei G, Balzarini J, De Clercq E. Antiviral enantiomeric preference for 5'-noraristeromycin. J Med Chem 1994;37: 551-4.
46. Siddiqi SM, Chen X, Rao J, Schneller SW, Ikeda S, Snoeck R, Andrei G, Balzarini J, De Clercq, E. 3-deaza- and 7-deaza- 5'-noraristeromycin and their antiviral properties. J Med Chem 1995;38: 1035-8.
47. Shuto S, Obara T, Toriya M, Hosoya M, Snoeck R, Andrei G, Balzarini J, De Clercq E. New neplanocin analogues. 1. Synthesis of 6'-modified neplanocin A derivatives as broadspectrum antiviral agents. J Med Chem 1992;35: 324-31.
48. Shuto S, Obara T, Saito Y, Yamashita K, Tanaka M, Sasaki T, Andrei G, Snoeck R, Neyts J, Padalko E, Balzarini J, De Clercq E, Matsuda A. New neplanocin analogues. VIII. Synthesis and biological activity of 6'-C-ethyl, -ethenyl, and -ethynyl derivatives of neplanocin A. Chem Pharm Bull 1997;45: 1163-8.
49. Cools M, Balzarini J, De Clercq, E. Mechanism of antiviral and cytotoxic action of (±)-6' beta-fluoroaristeromycin, a potent inhibitor of S-adenosylhomocysteine hydrolase. Mol Pharmacol 1991;39: 718-24.
50. Siddiqi SM, Chen X, Schneller SW, Ikeda S, Snoeck R, Andrei G, Balzarini J, De Clercq E. An epimer of 5'-norartisteromycin and its antiviral properties. J Med Chem 1994;37: 1382-4.
51. De Clercq E. John Montgomery's legacy: carbocyclic adenosine analogues as SAH hydrolase inhibitors with broadspectrum antiviral activity. Nucleosides Nucleotides Nucleic Acids 2005;24: 1395-1415.
52. De Clercq E. A cutting-edge view on the current state of antiviral drug development. Med Res Rev 2013;33: 1249-77.
53. De Clercq E. Dancing with chemical formulae of antivirals: A panoramic view (Part 2). Biochem Pharmacol 2013;86: 1397- 1410.
54. Smither SJ, Eastaugh LS, Steward, JA, Nelson M, Lenk RP, Lever MS. Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 2014;104: 153-5.
55. Oestereich L, Lüdtke A, Wurr S, Rieger T, Munoz-Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014;105: 17-21.
56. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S. Protection against filovirus diseases by a novel broadspectrum nucleoside analogue BCX4430. Nature 2014;508: 402-5.
57. Julander JG, Bantia S, Taubenheim BR, Minning DM, Kotian P, Morrey JD, Smee DF, Sheridan WP, Babu YS. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model. Antimicrob Agents Chemother 2014;58: 6607-14.
58. Descamps J, De Clercq E. Broad-spectrum antiviral activity of pyrazofurin (pyrazomycin). Curr Chemother 1978; 354-7.
59. Shannon WM. Selective inhibition of RNA tumor virus replication in vitro and evaluation of candidate antiviral agents in vivo. Ann NY Acad Sci 1977;284: 472-507.
60. Gutowski GE, Sweeney MJ, DeLong DC, Hamill RL, Gerzon K. Biochemistry and biological effects of the pyrazofurins (pyrazomycins): initial clinical trial. Ann NY Acad Sci 1975;255: 544-51.
61. Sweeney MJ, Davis FA, Gutowski GE, Hamill RL, Hoffman DH, Poore GA. Experimental antitumor activity of pyrazomycin. Cancer Res 1973;33: 2619-23.
62. Barton C, Kouokam JC, Lasnik AB, Foreman O, Cambon A, Brock G, Montefiori DC, Vojdani F, McCormick AA, O'Keefe BR, Palmer KE. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob Agents Chemother 2014;58: 120-7.
63. Balzarini J, Van Laethem K, Hatse S, Vermeire K, De Clercq E, Peumans W, Van Damme E, Vandamme AM, Bölmstedt A, Schols D. Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J Virol 2004;78: 10617-27.
64. Dwek RA, Butters TD, Platt FM, Zitzmann N. Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov 2002;1: 65-75.
65. Chang J, Warren TK, Zhao X, Gill T, Guo F, Wang L, Comunale MA, Du Y, Alonzi DS, Yu W, Ye H, Liu F, Guo JT, Mehta A, Cuconati A, Butters TD, Bavari S, Xu X, Block TM. Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res 2013;98: 432-40.
66. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011;477: 340-3.
67. Côté M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 2011;477: 344-8.
68. Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z, Grock A, Hong PW, Li J, Watson NF, Fang AQ, Aguilar HC, Porotto M, Honko AN, Damoiseaux R, Miller JP, Woodson SE Chantasirivisal S, Fontanes V, Negrete OA, Krogstad P, Dasgupta A, Moscona A, Hensley LE, Whelan SP, Faull KF, Holbrook MR, Jung ME, Lee B. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A 2010;107: 3157-62.
69. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehár J, Hensley LE, White JM, Olinger GG. FDAapproved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 2013;5: 190ra79.
70. Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, Pöhlmann S, Vondran FW, David S, Manns MP, Ciesek S, von Hahn T. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother 2014;69: 2123-31.
71. Savarino A, Gennero L, Sperber K, Boelaert JR. The anti- HIV-1 activity of chloroquine. J Clin Virol 2001;20: 131-5.
72. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004;323: 264-8.
73. Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, Kolokoltsov AA, Carrion R Jr, Patterson JL, Bavari S, Panchal RG, Warren TK, Wells JB, Moos WH, Burke RL, Tanga MJ. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One 2013;8: e60579.
74. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 2003;3: 722-7.